选择性T型钙通道阻滞剂米贝地尔与替莫唑胺时序序贯治疗复发性高级别胶质瘤患者
这项I期研究在27例复发性高级别胶质瘤患者中评估米贝地尔(MIB)序贯替莫唑胺(TMZ)的安全性和最大耐受剂量(MTD)。MIB的MTD为87.5 mg口服每日四次,剂量限制性毒性为丙氨酸氨基转移酶/天冬氨酸氨基转移酶升高(3级)和窦性心动过缓。MIB后接TMZ在该MTD下耐受良好,部分患者出现疗效反应,作者认为该方案值得进一步研究。
要点
- MIB序贯TMZ在复发性高级别胶质瘤患者中的MTD为87.5 mg口服每日四次。
- 剂量限制性毒性为丙氨酸氨基转移酶/天冬氨酸氨基转移酶升高(3级)和窦性心动过缓。
- 18F-FLT PET显示10例中2例在MIB治疗7天后标准化摄取值信号显著下降。
核心结论
- MIB后接TMZ在复发性高级别胶质瘤患者中按MTD给药耐受良好;该选定人群中无毒性且存在部分疗效反应,作者认为该方案值得进一步研究。
研究设计与样本
- I期研究,采用改良3+3设计进行MIB剂量递增,并在MTD处设10例扩展队列行18F-FLT PET成像。
- 入组27例复发性高级别胶质瘤成人患者(20例世界卫生组织IV级,7例III级;中位年龄50岁;中位KPS 90),距初始治疗TMZ≥3个月。
- MIB每日四次口服连续7天,随后每28天周期给予标准TMZ 150-200 mg/m2连续5天。
主要发现
- MIB的MTD为87.5 mg口服每日四次;剂量限制性毒性为丙氨酸氨基转移酶/天冬氨酸氨基转移酶升高(3级)和窦性心动过缓。
- MTD下MIB稳态最大血浆浓度为1693 ± 287 ng/mL(均值 ± 标准差)。
- 18F-FLT PET成像显示10例中2例在MIB治疗7天后标准化摄取值信号显著下降。
关键数值与推荐
- MIB最大耐受剂量:87.5 mg口服每日四次。
- TMZ给药方案:150-200 mg/m2连续5天,每28天周期。
- MIB稳态最大血浆浓度(MTD下):1693 ± 287 ng/mL(均值 ± 标准差)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mibefradil (MIB), previously approved for treatment of hypertension, is a selective T-type calcium channel blocker with preclinical activity in high-grade gliomas (HGGs). To exploit its presumed mechanism of impacting cell cycle activity (G1 arrest), we designed a phase I study to determine safety and the maximum tolerated dose (MTD) of MIB when given sequentially with temozolomide (TMZ) in recurrent (r)HGG. METHODS: Adult patients with rHGG ≥3 months from TMZ for initial therapy received MIB in 4 daily doses (q.i.d.) for 7 days followed by standard TMZ at 150-200 mg/m2 for 5 days per 28-day cycle. MIB dose escalation followed a modified 3 + 3 design, with an extension cohort of 10 patients at MTD who underwent 3'-deoxy-3'-18F-fluorothymidine (18F-FLT) PET imaging, to image proliferation before and after 7 days of MIB. RESULTS: Twenty-seven patients were enrolled (20 World Health Organization grade IV, 7 grade III; median age 50 y; median KPS 90). The MTD of MIB was 87.5 mg p.o. q.i.d. Dose-limiting toxicities were elevation of alanine aminotransferase/aspartate aminotransferase (grade 3) and sinus bradycardia. The steady-state maximum plasma concentration of MIB at the MTD was 1693 ± 287 ng/mL (mean ± SD). 18F-FLT PET imaging showed a significant decline in standardized uptake value (SUV) signal in 2 of 10 patients after 7 days of treatment with MIB. CONCLUSIONS: MIB followed by TMZ was well tolerated in rHGG patients at the MTD. The lack of toxicity and presence of some responses in this selected patient population suggest that this regimen warrants further investigation.
引用
- Holdhoff M, Ye X, Supko JG, et al. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro Oncol. 2017. PMID: 28371832. doi:10.1093/neuonc/nox020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。